Infant Bacterial Therapeutics AB (publ)
IBT-B.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$942.51M
Close$
Share Statistics
| Market cap | $942.51 Million |
|---|---|
| Enterprise Value | $833.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.84 |
| Beta | 0.36 |
| Outstanding Shares | 13,471,420 |
Return
| Return on Equity | -154.49% |
|---|---|
| Return on Assets | -68.14% |
| Return on Invested Capital | -156.23% |
Valuation & Multiples
| P/E Ratio | -11.89 |
|---|---|
| PEG | -21.59 |
| Price to Sales | - |
| Price to Book Ratio | 24.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.07 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
$-1.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-2.67
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Infant Bacterial Therapeutics AB (publ)
6 employees
CEO: Staffan Strömberg Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9...